Defining a Cancer Dependency Map

Cited by (1,075)

Items 401–500 of 1,075

1. Pan-cancer analyses identify oncogenic drivers, expression signatures, and therapeutic vulnerabilities in RHO GTPase pathway genes
   Rubén Fernández, Luis Francisco Lorenzo‐Martín, Vı́ctor Quesada, Xosé R. Bustelo · 2025 · Frontiers in Bioinformatics
2. Dynamic regulation of the oxidative stress response by the E3 ligase TRIP12
   Andrew J. Ingersoll, Devlon M. McCloud, Jane G. Hu, Michael Rapé · 2025 · Cell Reports
3. Drosophila and human cell studies reveal a conserved role for CEBPZ, NOC2L and NOC3L in rRNA processing and tumorigenesis
   G. Rambaldelli, Valeria Manara, Andrea Vutera Cuda, G. Bertalot, Marianna Penzo, Paola Bellosta · 2025 · Journal of Cell Science
4. The RING finger E3 ligase RNF25 protects DNA replication forks independently of its canonical roles in ubiquitin signaling
   Lilly F. Chiou, Gaith N. Droby, Deepika Jayaprakash, Jay Ramanlal Anand, Xingyuan Zhang, Yang Yang, Christine A. Mills, Thomas S. Webb, Natalie K. Barker, Jialiu Xie et al. · 2025 · Nature Communications
5. PTPN2 Inhibition Disrupts Mitochondrial Renewal and Blocks TFRC‐Mediated Mitophagy to Exert Anti‐Tumor Activities in ALK‐Positive Anaplastic Large Cell Lymphoma
   Wei-Ting Wang, Ziwen Duan, T. Xing, W. Hua, Kai Du, Chun-Yu Shang, Yi-fan Wu, Li Wang, Jian-Yong Li, R. Gao et al. · 2025 · Advancement of science
6. Low-amplitude copy number gains shape cancer through known and novel oncogenes with associated therapeutic vulnerabilities
   T. F. Eleveld, B. Ylstra, L. Looijenga · 2025 · Nucleic Acids Research
7. Elucidating the association between TLR-4 expression and the clinical course of glioblastoma leptomeningeal disease
   Victor M. Lu, Jay S. Chandar, Jesus R. Castro, D. Seetharam, Vaidya Govindarajan, Christian K. Ramsoomair, Jelisah F. Desgraves, Anna J. Hudson, Ashish H. Shah · 2025 · British Journal of Cancer
8. Cytidine diphosphate diacylglycerol synthase 2 is a synthetic lethal target in mesenchymal-like cancers
   Tim Arnoldus, Alex v. Vliet, Onno B. Bleijerveld, Adriaan F. H. de Groot, Qinglin Piao, Niek Blomberg, Désirée Schatton, Jing Ming Dong, Susan E. van Hal-van Veen, Rolf Harkes et al. · 2025 · Nature Genetics
9. Unsupervised cell line embedding using pairwise drug response correlation
   Yutae Kim, Doheon Lee · 2025 · Computational and Structural Biotechnology Journal
10. Systematic profiling of cancer‐fibroblast interactions reveals drug combinations in ovarian cancer
    Greta Gudoityte, Osheen Sharma, L. Leuenberger, E. Wallin, J. Fernebro, P. Östling, Rebecka Bergström, Johan Lindberg, U. Joneborg, Olli-P. Kallioniemi et al. · 2025 · Molecular Oncology
11. CellHit: a web server to predict and analyze cancer patients’ drug responsiveness
    Francesco Carli, Natalia De Oliveira Rosa, Simon Blotas, Pierluigi Di Chiaro, Luisa Bisceglia, Mariangela Morelli, Francesca Lessi, Anna Luisa Di Stefano, Chiara Maria Mazzanti, Gioacchino Natoli et al. · 2025 · Nucleic Acids Research
12. Inborn errors of immunity underlie clonal T cell expansions in large granular lymphocyte leukemia
    C. Bravo-Pérez, C. Gurnari, Jani Huuhtanen, Naomi Kawashima, L. Guarnera, Aashray Mandala, Nakisha Williams, Christopher Haddad, Michaela Witt, Serhan Unlu et al. · 2025 · Journal of Clinical Investigation
13. KBG syndrome-associated protein ANKRD11 regulates SETD5 expression to modulate rRNA levels and translation
    Shoko Sashiyama, Tadashi Nakagawa, Makiko Nakagawa, Masaki Hosogane, Yasuaki Watanabe, Honoka Ashitomi, Kazusa Yamane, Norihiro Shibuya, Toshiro Moroishi, Keiko Nakayama et al. · 2025 · iScience
14. On the Quest for Biomarkers: A Comprehensive Analysis of Modified Nucleosides in Ovarian Cancer Cell Lines
    Daniel A. Mohl, S. Lagies, Alexander Lonzer, Simon P. Pfäffle, P. Gross, Moritz Benka, M. Jäger, Matthias C. Huber, Stefan Günther, Dietmar A. Plattner et al. · 2025 · Cells
15. Assembly and reasoning over semantic mappings at scale for biomedical data integration
    C. Hoyt, Klas Karis, B. Gyori · 2025 · bioRxiv
16. Targeting the WSB2–NOXA axis in cancer cells for enhanced sensitivity to BCL-2 family protein inhibitors
    Dong-Yue Jiao, Kun Chang, Jiamin Jin, Ying-Ji Chen, Mo Ren, Yucong Zhang, Kun Gao, Yao-Ting Xu, Lixin Wang, Chen-Ji Wang · 2025 · bioRxiv
17. DyNDG: Identifying Leukemia-related Genes Based on Time-series Dynamic Network by Integrating Differential Genes
    A. Jin, Ju Xiang, Xiang-Mao Meng, Yue Sheng, Hong-Ling Peng, Min Li · 2025 · Genomics, Proteomics & Bioinformatics
18. Targeting the RBM39-MEK5 axis synergizes with bortezomib to inhibit the malignant growth of multiple myeloma
    Jia Liu, Zilu Zhang, Wen-bin Xu, Mingyuan Jia, Xin-Yi Zeng, Cheng-Yu Wu, Ze Fu, Xiaoguang Xu, Chenjing Ye, Chao Wu et al. · 2025 · Blood Advances
19. Succinate dehydrogenase activity supports de novo purine synthesis
    Mushtaq A Nengroo, Austin T Klein, Heather S. Carr, Olivia Vidal-Cruchez, Umakant Sahu, D. McGrail, N. Sahni, Peng Gao, J. Asara, Hardik Shah et al. · 2025 · bioRxiv
20. Discovery of new covalent inhibitors of monoacylglycerol lipase with the nitrile warhead via SCARdock
    Juanping Wang, Xiaoyu Shi, Junlai Wang, Qiang Zheng, Peipei Shao, Sen Liu · 2025 · Bioorganic Chemistry
21. Comprehensive transcriptome, miRNA and kinome profiling identifies new treatment options for personalized lung cancer therapy
    Shen Zhong, Yvonne Boergeling, Patrick Zardo, Danny David Jonigk, Jürgen T. Borlak · 2025 · Clinical and Translational Medicine
22. Study on the effects and mechanism of RRM2 on three gynecological malignancies.
    Luhan Yang, Hong-Ping Zhang, Jun-Feng Wang, Jing Ge, Rushan Hao, Junxu Yu, Bingrong Zheng · 2025 · Cellular Signalling
23. Predicting patient outcomes with gene-expression biomarkers from colorectal cancer organoids and cell lines
    A. V. Razumovskaya, M. O. Silkina, Andrey A. Poloznikov, Timur Kulagin, M. P. Raigorodskaya, N. A. Gorban, Anna V. Kudryavtseva, Maria Fedorova, B. Yа. Alekseev, Alexander Tonevitsky et al. · 2025 · Frontiers in Molecular Biosciences
24. Unbiased Drug Target Prediction Reveals Sensitivity to Ferroptosis Inducers, HDAC and RTK Inhibitors in Melanoma Subtypes
    I. Pla, Botond L. Szabolcs, P. N. Péter, Zsuzsanna Ujfaludi, Yonghyo Kim, Peter L. Horvatovich, Aniel Sanchez, Krzysztof Pawłowski, E. Wieslander, M. Kuras et al. · 2024 · International Journal of Dermatology
25. WD repeat domain 5 (WDR5) inhibitors: a patent review (2016-present)
    Jesse A. Coker, Shaun R. Stauffer · 2024 · Expert Opinion on Therapeutic Patents
26. Perturbation response decomposition enables biologically aligned generalization to unseen perturbations and cellular contexts
    Alexis Molina, Xin-Yi Zhang · 2026 · bioRxiv
27. CRISPR in clinical oncology: translational advances from molecular diagnostics to therapeutics
    Sam E. Grigg, Carolyn Shembrey, Mohamed Fareh, Piers A. Blombery, Jacob E. Corn, John Francis Seymour, Joshua M. L. Casan · 2026 · Nature Reviews Clinical Oncology
28. Cis and trans regulatory mechanisms of extrachromosomal DNA segregation
    Yi-Peng Xie, J. Lim, Wenyue Liu, C. Gilbreath, Xiaohui Sun, Kailiang Qiao, Y. Kim, Si-Han Wu · 2026 · Nature Cell Biology
29. Reductive death is averted by a conserved de novo lipogenic switch
    Fasih M. Ahsan, Jen F. Rotti, Armen I. Yerevanian, Sinclair W. Emans, Nicole L. Stuhr, Jose A. Aceves-Salvador, Wei Wang, Daniel J. Baker, Dimitra Pouli, Owen S. Skinner et al. · 2026 · Molecular Cell
30. Artificial Intelligence in drug discovery and development: current landscape, challenges, and future perspectives
    Attila A. Seyhan, Claudio Carini · 2026 · Critical Reviews in Oncology/Hematology
31. Patterns and drivers of 43,617 mosaic chromosomal alterations in blood
    David Shin-Hsiung Tang, Nolan Kamitaki, Ronen E. Mukamel, Simone Rubinacci, Po‐Ru Loh · 2026 · Nature Genetics
32. The Human Pleiotropic Map of GWAS Associations and Therapeutic Implications
    Yakov A. Tsepilov, Dániel Süveges, Daniel Considine, Szymon Szyszkowski, Xiangyu Jack Ge, Irene López Santiago, Polina V. Rusina, Tobi Alegbe, Vivien W. Ho, Kirill Tsukanov et al. · 2026 · bioRxiv (Cold Spring Harbor Laboratory)
33. Whole-genome doubling drives immune evasion by silencing antigen presentation
    P. Foidart, Zhe-Qi Li, Xin-Ran Cai, Marco Seehawer, D. Brown, Amatullah Tawawalla, P. Baldominos, Salma Parvin, J. Nishida, E. Rojas-Jimenez et al. · 2026 · Cancer Cell
34. Target discovery and drug design in the era of artificial intelligence
    Payton Fleming, Andrey A. Ivanov · 2026 · Medicinal Chemistry Research
35. Patient-derived pediatric brain tumor orthotopic xenografts and tumor organoids faithfully recapitulate primary tumors
    Justin Stephen Williams, Dana M. Farmer, Qianqian Li, Jake D. Friske, Jose A. Grenet, Sarah Robinson, Kimberly Mercer, Vanshita Goel, Laura J. Janke, Liusheng He et al. · 2026 · Science Advances
36. Discovery of a selective CDK7 PROTAC against acute leukemia with low platelet toxicity.
    Yu-Tong Tu, Xiaojia Cai, Zhao-Fan Tao, Ruisen Zhang, Xian Li, Bei-Jing Chen, Hua-Lin Zhang, Xiao-Bei Hu, Jiayi Ke, Xiaoya Chen et al. · 2026 · Leukemia
37. Restoring the tumour mechanophenotype of vocal fold cancer reverts its malignant properties
    Jasmin Kaivola, Karolina Punovuori, Megan R. Chastney, Hind Abdo, Gautier Follain, Mathilde Mathieu, Omkar Joshi, Yekaterina A. Miroshnikova, Fabian Krautgasser, Jasmin Di Franco et al. · 2026 · Nature Materials
38. The impact of epigenetics on tumor metabolism: Friend or foe in drug response?
    Serena Castelli, M. Franchini, Luigi Ferraro, Nicolò Mangraviti · 2026 · Frontiers in epigenetics and epigenomics
39. High-Throughput Drug Screening for Targeting Polyploid Cancer Cells with an Interactive Web Portal
    Hsiao-Chun Chen, Li-Ju Wang, Chien-Hung Shih, Huikang Ye, Ying-Ju Lai, Jinxiong Cheng, Yuan Zhang, Yushu Ma, Tiffany Habib, Shailrajsinh H Jhala et al. · 2026 · Cancer Letters
40. Discovery of KRAS-G12D degraders via exploration of various E3 ligases.
    Hyerin Yim, Xiang-Yang Song, Yue Zhong, Jacqueline Hu, Yan Xiong, Jian Jin · 2026 · European journal of medicinal chemistry
41. Functional nutrient-genetic profiling reveals biotin and FBXW7 are essential to bypass glutamine addiction
    Miriam Lisci, Fanny Vericel, Yifan Liu, Héctor Gallart‐Ayala, Julijana Ivanišević, Owen S. Skinner, Alexis A. Jourdain · 2026 · Molecular Cell
42. AI and Big Data in Oncology: A Physician‐Centered Perspective on Emerging Clinical and Research Applications
    Binliang Liu, Qingyao Shang, Jun Li, Shuna Yao, Meishuo Ouyang, Yu Wang, Sheng Luo, Quchang Ouyang · 2026 · Cancer Innovation
43. Surface Marker Identification to Capture Live Circulating Tumor Cells in Metastatic Triple-Negative Breast Cancer
    Bree M Lege, Khushali J. Patel, Brendan Panici, Ping Gong, Michael T. Lewis, M.J. Ellis, Chong-Hui Cheng · 2026 · Cancer Research Communications
44. Dual inhibition of the nonsense mediated mRNA decay enhances tumour immunogenicity, drives immunoediting, and potentiates checkpoint blockade
    Ivan Zadra, Davor Oršolić, Dimitri Kounis, Mario Acera, Guillermo Marquez, Etna Abad, L. Ortet, A. Benito, Y. Kharraz, Carlos M. Martínez et al. · 2025 · bioRxiv
45. DeepTarget predicts anti-cancer mechanisms of action of small molecules by integrating drug and genetic screens
    Sanju Sinha, Neelam Sinha, Marlenne Perales, Adi Tarrab, Trinh-Don Nguyen, Lihe Liu, T. Cantore, Kyle Alvarez, Sumeet Patiyal, S. Mukherjee et al. · 2025 · npj Precision Oncology
46. Diversity of BRAF mutations in non-small cell lung cancer and implications on treatment
    Kevin Lu, J. Shen, F. Lopez-Diaz, A. Leal, I. Mambetsariev, Kaushal Parikh, A. Hazim, B. Woodward, A. Madduri, Faisal Khurshid et al. · 2025 · npj Precision Oncology
47. Human clearance systems have a layered architecture across tissues and cell types that supports varied proteome compositions
    Ekaterina Vinogradov-Talyah, Bar Edri, Lior Ravkaie, Or Lazarescu, Fadi Gharra, Juman Jubran, Anat Ben-Zvi, Esti Yeger-Lotem · 2025 · Autophagy
48. CDK4/6 Inhibitors in Breast Cancer—Who Should Receive Them?
    Anran Chen, Ze-Yi Zheng, Meenakshi Anurag, Ahmed M. Elkhanany, Natalie Chen, Eric C. Chang · 2025 · International Journal of Molecular Sciences
49. GLA-Synergy: An Interpretable Global-Local Adaptive Framework for Drug Synergy Prediction in Cancer Treatment
    Lizhi Deng, Shiyu Yan, Jiaoxing Yang, Mingyong Li, Ping-Jian Ding · 2025 · Journal of Chemical Information and Modeling
50. Methylation-induced suppression of YAP/TAZ confers sensitivity to HDAC inhibitors in high-grade IDH mutant gliomas
    Thomas K. Sears, Matthew McCord, Wenxia Wang, Alicia Steffens, Kathleen McCortney, Rahul Kishore Chaliparambil, Jann Nagina Sarkaria, Craig Horbinski · 2025 · JCI Insight
51. Hypothesis Hunting with Evolving Networks of Autonomous Scientific Agents
    Tennison Liu, Silas Ruhrberg Est'evez, David L. Bentley, M. van der Schaar · 2025 · arXiv.org
52. The differential regulation of the urea cycle in tumors goes awry
    Ahmed M. Abou‐Shanab, Mennatallah A. Khedr, Sandro Matosevic · 2025 · Biochemical Pharmacology
53. Chromatin Regulatory Targets for Anticancer Therapeutics
    Paige A. Barta, Trever R. Carter, Michael A. Erb · 2025 · Chemical Reviews
54. Direct Protein Degradation: Emerging Tools to Probe Biological Complexity in Mammalian Systems
    Sailasree Rajalekshmi, Kizhakke Mattada Sathyan · 2025 · BioEssays
55. Genetic evidence informs the direction of therapeutic modulation in drug development
    Robert K. Chen, Áine Duffy, Joshua K. Park, David F. Stein, Avner Schlessinger, Yuval Itan, Benjamin Scott Glicksberg, Rory James Tinker, Daniel M. Jordan, Ghislain Rocheleau et al. · 2025 · npj Drug Discovery.
56. Machine learning integration with multi-omics data constructs a robust prognostic model and identifies PTGES3 as a therapeutic target for precision oncology in lung adenocarcinoma
    Lian-Jie Ruan, Kang-Qiang Weng, Wei-yu Zhang, Yao-Ning Zhuang, Jing Li, Li-Ming Lin, Yu-Tong Chen, Yi Zeng · 2025 · Frontiers in Immunology
57. Single-cell atlas of AML reveals age-related gene regulatory networks in t(8;21) AML
    Jessica Whittle, Stefan Meyer, Georges Lacaud, Syed Murtuza-Baker, Mudassar Iqbal · 2025 · bioRxiv
58. Identifying meaningful drug response biomarkers from public pharmacogenomic datasets with biologically informed interpretable neural networks
    Maoxin Ran, Shao-Lin Zhang, Kin-Yip Tam · 2025 · Comput. Biol. Chem.
59. Neural interaction explainable AI predicts drug response across cancers
    Philipp Keyl, Julius Keyl, Andreas Möck, Gabriel Dernbach, Liliana H. Mochmann, Niklas Kiermeyer, Philipp Sebastian Jurmeister, Michael Ludwig Bockmayr, Roland F. Schwarz, Grégoire Montavon et al. · 2025 · NAR Cancer
60. Inter- and intra-tumoral ALDH1 heterogeneity in breast cancer identifies therapeutic opportunities for ALDH1A-specific inhibitors.
    R. Pequerul, A. Constantinescu, B. Janji, Akinchan Kumar, C. Baier, I. Manosalva, Xavier Parés, Oscar Palacios, S. Spicuglia, Delphine Colignon et al. · 2025 · Cell Chemical Biology
61. In vivo manipulation of the protein homeostasis network in rhabdomyosarcoma
    Kristen Kwong, Yue Pan, Jacqueline Morales, Matthew Watson, David V. Allegakoen, Alex Gia Lee, Trever Grant Bivona, Peter Wipf, Christopher J. Guerriero, Jeffrey L. Brodsky et al. · 2025 · Oncotarget
62. Discovery of Macrocyclic Myeloid Cell Leukemia 1 (Mcl-1) Inhibitors that Demonstrate Potent Cellular Efficacy and In Vivo Activity in a Mouse Solid Tumor Xenograft Model
    J. C. Tarr, K. Jeon, Nagarathanam Veerasamy, M. Aichinger, James M. Salovich, Bin Zhao, J. Sensintaffar, Heribert Arnhof, Tobias Wunberg, Danielle Sgubin et al. · 2025 · Journal of Medicinal Chemistry
63. A stem cell differentiation model reveals two alternative fates in CBFA2T3::GLIS2-driven acute megakaryoblastic leukemia initiation
    Mohamed R. Shoeb, Dagmar Schinnerl, Lisa Ellen Shaw, Matthias Farlik, Sabine Strehl, Florian Halbritter, Klaus Fortschegger · 2025 · Communications Biology
64. Cellf-deception: human microglia clone 3 (HMC3) cells exhibit more astrocyte-like than microglia-like gene expression
    Kylee K. Rahm, Branden S. Kinghorn, Myanna J. Moody, Ben C. Stone, Kaitlyn Strong, Brian S. Kim, Yen Jou Chang, Samantha Sleight, Alyssa A. Nitz, David V. Hansen et al. · 2025 · Frontiers in Bioinformatics
65. Loss of NOTCH2 creates a TRIM28-dependent vulnerability in small cell lung cancer.
    De-Li Hong, Ying Lyu, Richa Nayak, J. Becker, Matthew A. Booker, Keita Masuzawa, Zoe Devos, Tian-Chu Wang, Shin Saito, Qi Liu et al. · 2025 · Developmental Cell
66. Acute degradation of nucleolin reveals its novel functions in cell cycle progression and cell division in triple negative breast cancer
    Joseph Mills, A. Tessari, Vollter Anastas, Damu Sunilkumar, Nastaran Samadi Rad, Saranya Lamba, Ilaria Cosentini, Ashley B. Reers, Zirui Zhu, Wayne O. Miles et al. · 2025 · Journal of experimental & clinical cancer research : CR
67. The small GTPase ARF6 regulates sphingolipid homeostasis and supports proliferation in acute myeloid leukemia
    Helong Gary Zhao, Nataly Cruz-Rodriguez, Kent C Johnson, A. Pomicter, Briana Bates, Benjamin Bateman, T. Haferlach, Tong-Jun Gu, Jonathan M. Ahmann, Dongqing Yan et al. · 2025 · Haematologica
68. Z-scores outperform similar methods for analyzing CRISPR paralog synthetic lethality screens
    Jui-Hsuan Chou, Nazanin Esmaeili Anvar, Reem Elghaish, J. Chen, Traver Hart · 2025 · Genome Biology
69. Alternative Lengthening of Telomeres: The Need for ATRX Mutations Is Lineage-Dependent
    Ion Udroiu, Antonella Sgura · 2025 · International Journal of Molecular Sciences
70. Patients with systemic lupus erythematosus (SLE) have an increased bisphenol A methylation score linked to SLE risk genes and selected clinical subphenotypes
    H. Vestin, N. Oparina, M. Eloranta, M. Frodlund, I. Gunnarsson, C. Sjöwall, E. Svenungsson, L. Rönnblom, J. Imgenberg-Kreuz, D. Leonard · 2025 · RMD Open
71. System Theoretic Methods in Drug Discovery and Vaccine Formulation, Review and Perspectives
    Ankita Sharma, Yen-Che Hsiao, Abhishek Dutta · 2025 · Social Science Research Network
72. Causality-aware graph neural networks for functional stratification and phenotype prediction at scale
    Charalampos P. Triantafyllidis, Ricardo Aguás · 2025 · bioRxiv
73. Genome‐Scale CRISPR‐Cas9 Analysis Reveals Tumor Heterogeneity and Identifies NDC80 as Novel Biomarker in HCC
    Zhipu Liu, Long Liu, Shu-Tong Liu, Y. Ba, An-Ning Zuo, Hui-Xian Xu, Yu-Yuan Zhang, Senyan Wang, Li-Bo Wang, Xin-Wei Han · 2025 · Journal of Gastroenterology and Hepatology
74. Xanthine oxidoreductase expression is diminished in breast cancer as a response to uric acid mediated chelation of redox active iron
    Matthew G. Chapa, Rita King, Z.W. Dean, A. Maskey, R.M. Park, M. Velayutham, Elena N. Pugacheva, Owen M. Woodward, B.A. Webb, Douglas R. Spitz et al. · 2025 · Free Radical Biology and Medicine
75. Allelic expression patterns of imprinted and non-imprinted genes in cancer cell lines from multiple histologies
    Julia Krushkal, Travis L. Jensen, George Wright, Yingdong Zhao · 2025 · Clinical Epigenetics
76. USP37 protects mammalian cells during DNA replication stress by counteracting CUL2LRR1 and TRAIP.
    Fabrizio Villa, Johanna Ainsworth, Karim P. M. Labib · 2025 · Cell Reports
77. Interpretable neural networks prioritize cancer driver genes from genome-wide dependency landscapes
    Qing-Yang Yin, Liang Chen · 2025 · bioRxiv
78. Inhibition of NAMPT as a Therapeutic Strategy to Suppress Tumor Growth in Lymphangioleiomyomatosis
    Shahrzad Soleymani Fard, Nandini Kundu, Alek S. Torres, Christina Faltas, J. D. Di Martino, Marina K. Holz · 2025 · Biochimica et biophysica acta. Molecular cell research
79. Incomplete paralog compensation generates selective dependency on TRA2A in cancer
    Amanda R. Lee, Anna Tangiyan, Isha Singh, Peter S. Choi · 2025 · PLoS Genetics
80. Cancer Dependency Map: Past and Present
    Rand Arafeh, Tsukasa Shibue, Francisca Vázquez, William C. Hahn · 2025 · Annual Review of Cancer Biology
81. Characterization of exoribonuclease XRN1 as a cancer target and identification of adenosine-3’,5’-bisphosphate as a potent enzyme inhibitor
    G.J. Lockbaum, Maureen M. Lynes, Sophie A. Shen, Julie X. Liu, Nicholas Holt, Sunaina P. Nayak, Kevin E. Knockenhauer, Shihua Yao, E. Allen Sickmier, Anugraha Raman et al. · 2025 · Communications Biology
82. ATF4:p52 Complex Activates Oncogenic Enhancers in Multiple Myeloma via p300/CBP Recruitment to Regulate BACH1.
    D. A. Ang, Nathan Harmston, Yinghui Li · 2025 · Cancer Letters
83. Inferring Drug–Gene Relationships in Cancer Using Literature-Augmented Large Language Models
    Ying-Ju Lai, Li-Ju Wang, Tyler M. Yasaka, Yun‐A Shin, Michael Ning, Yanhao Tan, Chien-Hung Shih, Yibing Guo, Po-Yuan Chen, Hugh Galloway et al. · 2025 · Cancer Research Communications
84. Pathway activation model for personalized prediction of drug synergy
    Quang Thinh Trac, Yue Huang, T. Erkers, P. Östling, Anna Bohlin, A. Österroos, Mattias Vesterlund, R. Jafari, Ioannis Siavelis, H. Backvall et al. · 2025 · bioRxiv
85. SRBD1, a highly conserved gene required for chromosome individualization.
    J. Raaijmakers, L. M. Janssen, A. Mazouzi, Amber L.H. Hondema, Razvan Borza, A. Fish, A. Elbatsh, Justina Kazokaitė-Adomaitienė, Nuria Vaquero-Siguero, I. Mayayo-Peralta et al. · 2025 · Cell Reports
86. AI‐Driven Variant Annotation for Precision Oncology in Breast Cancer
    Kriti Shukla, Yue Wang, P. Spanheimer, Elizabeth C. Brunk · 2025 · bioRxiv
87. Superior preclinical efficacy of co-treatment with BRG1/BRM and FLT3 inhibitor against AML cells with FLT3 mutations
    W. Fiskus, Christopher P. Mill, J. Piel, M. Collins, M. Hentemann, Branko Cuglievan, Christine E. Birdwell, Kaberi Das, Hanxi Hou, John A. Davis et al. · 2025 · Blood Cancer Journal
88. Accurate prediction of multiple RNA modifications from nanopore direct RNA sequencing data with RNANO
    Linshu Wang, Tian-Hao Li, Yuan Zhou · 2025 · bioRxiv
89. Increasing RB1 Expression by Targeting EZH2 in Triple‐Negative Breast Cancer
    Renfei Yang, Liyan Fei, Yingfei Xue, Yu Zhang, Qian Hu, Lu Guo, Yong Wei, Qin Wu · 2025 · Journal of Cellular and Molecular Medicine
90. Identification of CACNB1 protein as an actionable therapeutic target for hepatocellular carcinoma via metabolic dysfunction analysis in liver diseases: An integrated bioinformatics and machine learning approach for precise therapy
    Jing Sun, Run Shi, Zhaokai Zhou, Weilong Xu, Jiaxuan Huai, Yutian Cao, Wenhui Zhang, Lijuan Nie, Gaoxiang Wang, Qianhua Yan et al. · 2025 · International Journal of Biological Macromolecules
91. Flipons enable genomes to learn by intermediating the exchange of energy for information
    Alan G. Herbert · 2025 · Journal of The Royal Society Interface
92. Amyloids in bladder cancer hijack cancer-related proteins and are positive correlated to tumor stage
    Diego Alem, César X. García-Laviña, Francisco Garagorry, Dardo Centurión, Joaquina Farías, Hany Pazos-Espinosa, María Noel Cuitiño-Mendiberry, Carolina Villadóniga, Susana Castro‐Sowinski, Martín Fló et al. · 2025 · Scientific Reports
93. Utilizing genomics to identify novel immunotherapeutic targets in multiple myeloma high-risk subgroups
    Enze Liu, Oumaima Jaouadi, Riya Sharma, Nathan J. Becker, Travis S. Johnson, Parvathi Sudha, Vivek S. Chopra, Faiza Zafar, Habib Hamidi, Charlotte Pawlyn et al. · 2025 · Genome Medicine
94. Multiomics Analysis Reveals Neuroblastoma Molecular Signature Predicting Risk Stratification and Tumor Microenvironment Differences.
    Xing Zhou, Zhao-Kai Zhou, Xiaohan Qin, Jian Cheng, Yongcheng Fu, Yuanyuan Wang, Jingyue Wang, Pan Qin, Da Zhang · 2025 · Journal of Proteome Research
95. Specificity and sensitivity of ALT‐associated markers in cancer cells
    I. Udroiu, Jessica Marinaccio, Romina Stella Goffi, Emanuela Micheli, A. Sgura · 2025 · FEBS Letters
96. Targeting the mitotic kinase NEK2 enhances CDK4/6 inhibitor efficacy by potentiating genome instability
    Jessica R. Bobbitt, Leslie Cuellar-Vite, Kristen L. Weber-Bonk, Marlee R. Yancey, Parth R. Majmudar, Ruth A. Keri · 2025 · Journal of Biological Chemistry
97. HypoEvolve: Genetic Algorithms Enable Multi-Agent LLMs to Discover Scientific Hypotheses
    Jie-Yuan Liu, Meng-Zhou Hu, Jefferson Chen, JungHo Kong, Pratibha Jagannatha, Yi-Ming Gao, Dexter Pratt, Hsin-Yu Lee, Zhi-Ting Hu, T. Ideker et al. · 2026
98. Preclinical characterization and phase 1 clinical testing of targeting mitochondrial peroxiredoxin 3 in cancer
    V. Gibson, Joanna Dzialo, T. Messier, A. Bzura, C. Poile, J. Rogel, J. Hahne, Aida Habibovic, Stephanie Stead, Alexis Saaman et al. · 2026 · Nature Communications
99. Aneuploidy selects for the acquisition of driver genes in breast cancer
    K. Al-Zahrani, Ellen Langille, Jocelyn Nurtanto, A. Obersterescu, Katie Teng, Christopher Lowden, Julien Dessapt, Cynthia H. Chiu, L. Caldwell, David P. Cook et al. · 2026 · Nature
100. Hypoxia rescues complex 1-associated disease caused by proteostatic defects
     Ankur Garg, Brandon R. Desousa, Raju Roy, Amy Flis, Skyler Y. Blume, Yohei Abe, Arthur A Melo, Ryan R. Cupo, Gabriela Grigorean, Daniel R. Southworth et al. · 2026 · Nature Metabolism